The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of applications, especially for therapeutics. In this study, we assess the impact of these side chains on plasma pharmacokinetics of modified aptamers conjugated to a 40 kDa polyethylene glycol. We show that clearance from plasma depends on relative hydrophobicity: side chains with a negative cLogP (more hydrophilic) result in slower plasma clearance compared with side chains with a positive cLogP (more hydrophobic). We show that clearance increases with the number of side chains in sequences of ≥28 synthons, but this effect is dramatically diminished in shorter sequences. These results serve as a guide for the design of new therapeutic aptamers with diversity-enhancing side chains.
CITATION STYLE
Gupta, S., Drolet, D. W., Wolk, S. K., Waugh, S. M., Rohloff, J. C., Carter, J. D., … Janjic, N. (2017). Pharmacokinetic Properties of DNA Aptamers with Base Modifications. Nucleic Acid Therapeutics, 27(6), 345–353. https://doi.org/10.1089/nat.2017.0683
Mendeley helps you to discover research relevant for your work.